Calamos Advisors LLC Purchases 24,147 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Calamos Advisors LLC grew its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 27.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 110,671 shares of the medical device company's stock after acquiring an additional 24,147 shares during the quarter. Calamos Advisors LLC owned 0.23% of AtriCure worth $3,382,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ATRC. Champlain Investment Partners LLC raised its stake in AtriCure by 4.3% in the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock valued at $78,253,000 after purchasing an additional 115,813 shares in the last quarter. Wellington Management Group LLP raised its stake in AtriCure by 0.4% in the third quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company's stock valued at $43,291,000 after purchasing an additional 6,045 shares in the last quarter. State Street Corp raised its stake in AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after purchasing an additional 63,002 shares in the last quarter. Geode Capital Management LLC raised its stake in AtriCure by 2.9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after purchasing an additional 32,676 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in AtriCure by 14.6% in the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock valued at $18,621,000 after purchasing an additional 84,700 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Needham & Company LLC boosted their target price on AtriCure from $40.00 to $51.00 and gave the stock a "buy" rating in a research note on Wednesday, January 22nd. Oppenheimer boosted their target price on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on AtriCure from $53.00 to $61.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. UBS Group upped their price objective on AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. reaffirmed an "overweight" rating and issued a $40.00 price objective on shares of AtriCure in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $43.38.

AtriCure Trading Up 0.1 %

Shares of AtriCure stock traded up $0.04 on Friday, reaching $41.00. 480,328 shares of the company's stock were exchanged, compared to its average volume of 590,066. The company has a market capitalization of $2.00 billion, a P/E ratio of -49.40 and a beta of 1.46. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The firm's 50-day moving average is $35.19 and its two-hundred day moving average is $30.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.